|
Product
Anti-cancer Products (Cytoplatin)
|
Anti-cancer Products (Cytoplatin)
|
|
| |
|
Cytoplatin
Cytoplatin Injection
COMPOSITION
Cytoplatin-50 Aqueous Injection
Each 50 ml vial contains Cisplatin USP 50 mg, Sodium Chloride IP 0.9% w/
v and water for injection IP q.s.
Indications
Cytoplatin is indicated only for the treatment of malignancies. It is indicated
for use in metastatic ovarian cancer, advanced bladder cancer, metastatic
testicular cancer, small cell carcinoma of the lung, nonsmall cell carcinoma
of the lung, squamous cell carcinoma of the oesophagus, head and neck
cancers.
Dosage and Administration
Note: Needles or intravenous sets containing aluminium parts that may
come in contact with Cytoplatin should not be used for preparation or
administration. Aluminium reacts with Cytoplatin, causing precipitate
formation and a loss of potency.
|
Precautions for administration
The aqueous solution should be used intravenously only and should be
administered by intravenous infusion over a 6 to 8-hour period.
Skin reactions associated with accidental exposure to cisplatin may occur.
Pretreatment hydration with 1 to 2 1itres of fluid infused for 8 to 12 hours
prior to a Cytoplatin dose is recommended. Do not dilute Cytoplatin in just
5% dextrose injection. Adequate hydration and urinary output must be
maintained during the following 24 hours.
Dosage of Cytoplatin must be based on the clinical, renal, hematologic
and otic response. The usual dose of Cytoplatin is 50-100 mg/m 2 as a
single intravenous administration or 20 mg/m 2 intravenously daily for 5
consecutive days. The dose can be adjusted, depending on combination
with other cytotoxic agents. A course of Cytoplatin therapy should be
administered once every 3-4 weeks, depending on results of renal function
tests, blood tests and audiometric tests.
Contraindications
Hypersensitivity to cisplatin or other platinum-containing compounds.
Presentation
Cytoplatin-50 Vial of 50 ml
|
|
